|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8710 EUR | +3.69% |
|
-0.80% | -26.06% |
| 06-02 | NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation | CI |
| 06-02 | NFL Biosciences validates breakthrough in personalized medicine |  |
Company Valuation: NFL Biosciences
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 12.56 | 10.29 | 11.67 | 19.12 | 14.93 |
| Change | - | -18.12% | 13.49% | 63.78% | -21.92% |
| Enterprise Value (EV) 1 | 9.443 | 9.155 | 9.206 | 17.05 | 13.31 |
| Change | - | -3.05% | 0.56% | 85.17% | -21.93% |
| P/E | -12.8x | -4.21x | -3.14x | -9.56x | -4.62x |
| PBR | 3.82x | 12.2x | 33.6x | 19.8x | 48.8x |
| PEG | - | -0x | 1.88x | 0.2x | -0.2x |
| Capitalization / Revenue | 322,130x | 467,546x | 58.4x | 415,647x | 79,404x |
| EV / Revenue | 242,134x | 416,129x | 46x | 370,592x | 70,790x |
| EV / EBITDA | -11x | -3.02x | -2.21x | -6.26x | -3.51x |
| EV / EBIT | -10.5x | -2.97x | -2.18x | -6.11x | -3.44x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.1869 | -0.4668 | -0.459 | -0.206 | -0.255 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | 0.000039 | 0.000022 | 0.2 | 0.000046 | 0.000188 |
| EBITDA 1 | -0.8584 | -3.031 | -4.174 | -2.723 | -3.786 |
| EBIT 1 | -0.9019 | -3.083 | -4.23 | -2.79 | -3.873 |
| Net income 1 | -0.9782 | -2.443 | -3.745 | -2.081 | -3.318 |
| Net Debt 1 | -3.12 | -1.131 | -2.467 | -2.073 | -1.619 |
| Reference price 2 | 2.4000 | 1.9650 | 1.4400 | 1.9700 | 1.1780 |
| Nbr of stocks (in thousands) | 5,235 | 5,235 | 8,107 | 9,705 | 12,672 |
| Announcement Date | 29/4/22 | 28/4/23 | 14/4/25 | 14/4/25 | 27/4/26 |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 12.14M | |
| 34.2x | 8.53x | 26.72x | 0.05% | 55.63B | |
| 19.78x | 6x | 13.04x | 1.52% | 52.25B | |
| -18.16x | 4.33x | -7.56x | -.--% | 23.07B | |
| -39.15x | 12.94x | -37.74x | -.--% | 22.41B | |
| 22.36x | 4.48x | 14.84x | -.--% | 15.94B | |
| 17.25x | 5x | 11.74x | -.--% | 13.77B | |
| 44.46x | 16.86x | 51x | -.--% | 13.47B | |
| -74.63x | 7.55x | -67.7x | -.--% | 11.82B | |
| -12.71x | 97.46x | -14.44x | -.--% | 11.16B | |
| Average | -0.73x | 18.13x | -1.12x | 0.18% | 21.95B | |
| Weighted average by Cap. | 8.24x | 12.40x | 5.79x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALNFL Stock
- Valuation NFL Biosciences
Select your edition
All financial news and data tailored to specific country editions
